Infinity Pharmaceuticals Announces Conference Call for the ASCO Genitourinary Cancers Symposium to Discuss Clinical Data from MARIO-275 Phase 2 Study

Rhea-AI Summary

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced a conference call on February 11, 2021, at 7:30 a.m. ET to discuss clinical data from the MARIO-275 study. This Phase 2, randomized, placebo-controlled study evaluates eganelisib combined with Opdivo in I/O naïve urothelial cancer. Infinity is advancing eganelisib, a potential first-in-class immuno-oncology therapeutic targeting immune suppression in cancer, in multiple clinical studies, including various combinations with other therapies.

Positive

• Conducting a Phase 2 study (MARIO-275) evaluating eganelisib's efficacy combined with Opdivo, which could enhance treatment options for urothelial cancer.
• Eganelisib is being tested in multiple studies, indicating robust development and potential market opportunity.

Negative

• None.

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, which addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that it will hold a conference call on Thursday, February 11, 2021 at 7:30 a.m. ET to discuss clinical data from MARIO-275 (Macrophage Reprogramming In Immuno-Oncology), a Phase 2 randomized, placebo-controlled study of eganelisib combined with Opdivo^® (nivolumab) in I/O naïve urothelial cancer.

Conference Call Information

A live webcast of the conference call can be accessed in the "Investors/Media" section of Infinity's website at www.infi.com. To participate in the conference call, please dial (877) 316-5293 (domestic) and (631) 291-4526 (international) five minutes prior to start time. The conference ID number is 2485636. An archived version of the webcast will be available on Infinity's website for 30 days.

ASCO Genitourinary Cancers Symposium Poster Presentation Details
Title:			Preliminary Analysis of a Phase 2, Multicenter, Randomized, active-Control Study to Evaluate the Efficacy and Safety of Eganelisib (IPI-549) in Combination with Nivolumab Compared to Nivolumab Monotherapy in Patients with Advanced Urothelial Carcinoma
Presenter:			Piotr Tomczak, M.D., Ph.D.
Date:			February 11th at 8am ET

About Infinity and Eganelisib

Infinity is an innovative biopharmaceutical company dedicated to developing novel medicines for people with cancer. Infinity is advancing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, in multiple clinical studies. MARIO-275 is a Phase 2, randomized, placebo-controlled study of eganelisib combined with Opdivo in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq^® and Abraxane^® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (dual adenosine receptor antagonist) plus Doxil^® in advanced TNBC patients. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line and second line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Opdivo^® is a registered trademark of Bristol Myers Squibb.
Tecentriq^® is a registered trademark of Genentech, Inc.
Abraxane^® is a registered trademark of Abraxis BioScience, LLC a wholly owned subsidiary of Bristol Myers Squibb Company.
Avastin^® is a registered trademark of Genentech, Inc.
Doxil^® is a registered trademark of Baxter Healthcare Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210210005916/en/

FAQ

What is the MARIO-275 study for Infinity Pharmaceuticals?

The MARIO-275 study is a Phase 2 randomized, placebo-controlled trial evaluating the efficacy of eganelisib combined with Opdivo in I/O naïve urothelial cancer.

When will Infinity Pharmaceuticals discuss the MARIO-275 study results?

Infinity Pharmaceuticals will discuss the MARIO-275 study results during a conference call on February 11, 2021, at 7:30 a.m. ET.

What are the potential implications of the MARIO-275 study for eganelisib?

If successful, the MARIO-275 study could position eganelisib as a first-in-class treatment in urothelial cancer, potentially impacting market dynamics and revenue opportunities.

What is eganelisib and its role in cancer treatment?

Eganelisib is an oral immuno-oncology therapeutic being developed by Infinity Pharmaceuticals to reprogram macrophages and address immune suppression in cancer.